Helix Biopharma Corp
TSX:HBP
Helix Biopharma Corp
TSX:HBP
Price:
1.88
CAD
Market Closed
Market Cap:
CA$143.6m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Helix Biopharma Corp
TSX:HBP
|
CA |
|
Y
|
Yubo International Biotech Ltd
OTC:YBGJ
|
CN |
|
Concordia Financial Group Ltd
TSE:7186
|
JP |
|
Melodiol Global Health Ltd
ASX:ME1
|
AU |
Balance Sheet
Balance Sheet Decomposition
Helix Biopharma Corp
Helix Biopharma Corp
Balance Sheet Decomposition is not available for
Helix Biopharma Corp
Helix Biopharma Corp
Balance Sheet
Helix Biopharma Corp
Helix Biopharma Corp
Currency: CAD
| Jul-2002 | Jul-2003 | Jul-2004 | Jul-2005 | Jul-2006 | Jul-2007 | Jul-2008 | Jul-2009 | Jul-2010 | Jul-2011 | Jul-2012 | Jul-2013 | Jul-2014 | Jul-2015 | Jul-2016 | Jul-2017 | Jul-2018 | Jul-2019 | Jul-2020 | Jul-2021 | Jul-2022 | Jul-2023 | Jul-2024 | Jul-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||||||||||
| Cash & Cash Equivalents |
3
|
2
|
4
|
4
|
4
|
11
|
19
|
14
|
13
|
19
|
5
|
4
|
7
|
7
|
4
|
1
|
0
|
0
|
4
|
4
|
3
|
1
|
1
|
0
|
|
| Cash |
3
|
2
|
4
|
4
|
4
|
11
|
19
|
14
|
13
|
19
|
5
|
4
|
7
|
7
|
4
|
1
|
0
|
0
|
4
|
4
|
3
|
1
|
1
|
0
|
|
| Short-Term Investments |
9
|
7
|
3
|
2
|
7
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
1
|
1
|
0
|
0
|
1
|
1
|
0
|
1
|
1
|
2
|
1
|
1
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accounts Receivables |
1
|
1
|
0
|
0
|
1
|
1
|
0
|
1
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
1
|
0
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Assets |
13
|
10
|
7
|
8
|
12
|
13
|
20
|
17
|
16
|
22
|
6
|
5
|
7
|
7
|
4
|
2
|
1
|
1
|
5
|
4
|
4
|
1
|
1
|
0
|
|
| PP&E Net |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
2
|
2
|
2
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| PP&E Gross |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
2
|
2
|
2
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
1
|
1
|
1
|
2
|
2
|
2
|
3
|
3
|
2
|
2
|
3
|
3
|
3
|
3
|
3
|
2
|
2
|
0
|
2
|
2
|
2
|
2
|
2
|
1
|
|
| Intangible Assets |
0
|
5
|
4
|
2
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
18
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
14
N/A
|
16
+13%
|
13
-23%
|
11
-8%
|
15
+35%
|
14
-8%
|
22
+52%
|
19
-11%
|
18
-6%
|
24
+35%
|
8
-69%
|
6
-23%
|
8
+34%
|
8
-1%
|
4
-43%
|
2
-51%
|
1
-47%
|
1
-18%
|
5
+422%
|
4
-17%
|
4
-8%
|
1
-72%
|
1
+45%
|
19
+1 163%
|
|
| Liabilities | |||||||||||||||||||||||||
| Accounts Payable |
1
|
1
|
1
|
1
|
2
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
1
|
0
|
1
|
1
|
2
|
3
|
1
|
1
|
1
|
0
|
1
|
2
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
1
|
1
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
2
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
| Total Current Liabilities |
1
|
1
|
1
|
1
|
2
|
2
|
1
|
2
|
2
|
2
|
1
|
1
|
1
|
1
|
1
|
2
|
3
|
4
|
2
|
4
|
3
|
2
|
2
|
3
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
0
|
0
|
0
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
1
N/A
|
1
-51%
|
1
+77%
|
1
-11%
|
2
+38%
|
2
-3%
|
1
-26%
|
2
+98%
|
2
+4%
|
2
-4%
|
1
-38%
|
1
-32%
|
1
+9%
|
1
-7%
|
1
+34%
|
2
+69%
|
3
+21%
|
4
+58%
|
3
-41%
|
5
+117%
|
3
-38%
|
2
-45%
|
2
-16%
|
3
+104%
|
|
| Equity | |||||||||||||||||||||||||
| Common Stock |
32
|
37
|
39
|
44
|
52
|
57
|
72
|
82
|
91
|
102
|
102
|
101
|
107
|
112
|
116
|
121
|
126
|
130
|
137
|
140
|
148
|
152
|
159
|
179
|
|
| Retained Earnings |
19
|
23
|
29
|
37
|
43
|
50
|
59
|
73
|
84
|
92
|
110
|
105
|
110
|
124
|
135
|
144
|
150
|
156
|
160
|
169
|
185
|
197
|
206
|
212
|
|
| Additional Paid In Capital |
0
|
1
|
2
|
4
|
5
|
6
|
7
|
8
|
9
|
12
|
13
|
9
|
10
|
18
|
22
|
23
|
23
|
23
|
26
|
28
|
38
|
44
|
47
|
48
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
13
N/A
|
15
+20%
|
11
-27%
|
10
-8%
|
14
+35%
|
13
-8%
|
21
+61%
|
17
-17%
|
16
-8%
|
22
+40%
|
6
-72%
|
5
-21%
|
7
+38%
|
7
+0%
|
3
-54%
|
0
N/A
|
2
-7 550%
|
3
-114%
|
2
N/A
|
1
N/A
|
0
N/A
|
1
N/A
|
0
+89%
|
16
N/A
|
|
| Total Liabilities & Equity |
14
N/A
|
16
+13%
|
13
-23%
|
11
-8%
|
15
+35%
|
14
-8%
|
22
+52%
|
19
-11%
|
18
-6%
|
24
+35%
|
8
-69%
|
6
-23%
|
8
+34%
|
8
-1%
|
4
-43%
|
2
-51%
|
1
-47%
|
1
-18%
|
5
+422%
|
4
-17%
|
4
-8%
|
1
-72%
|
1
+45%
|
19
+1 163%
|
|
| Shares Outstanding | |||||||||||||||||||||||||
| Common Shares Outstanding |
22
|
24
|
25
|
27
|
33
|
36
|
46
|
53
|
60
|
67
|
67
|
67
|
76
|
85
|
89
|
96
|
103
|
111
|
133
|
28
|
34
|
40
|
49
|
74
|
|
Switch to:
Switch to:
See Also
Discover More
